SCHEMBL15980752

SCHEMBL15980752

C=C(C)/C=C/c1cn(C)c2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.62
MEN1 O00255 6/20 0.62
MAPT P10636 6/20 0.62
RAB9A P51151 2/20 0.62
NPC1 O15118 2/20 0.62
CASP3 P42574 1/20 0.62
SENP8 Q96LD8 1/20 0.62
SENP7 Q9BQF6 1/20 0.62
SENP6 Q9GZR1 1/20 0.62
ALDH1A1 P00352 6/20 0.56
IMPDH2 P12268 1/20 0.56
GAA P10253 4/20 0.46
ATM Q13315 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 2/20 0.46
MAPK1 P28482 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CRHBP P24387 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14756766 0.84 MAPT (0.71) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL8494188 0.82 KMT2A (0.73) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL8494191 0.82 KMT2A (0.73) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL2940762 0.81 MEN1 (0.76) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL2940766 0.81 MEN1 (0.76) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL15980753 0.80 MAPT (0.54) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL14099508 0.80 ALDH1A1 (0.62) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL23046854 0.79 KMT2A (0.69) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL17529416 0.79 KMT2A (0.69) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL22713034 0.78 KMT2A (0.68) KMT2AMEN1MAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243321-A1 BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 US disclosed
US-20140243286-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 US disclosed
US-20140243322-A1 BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243322-A1 BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME BRDT, BRD2, BRD4 KMT2A 408/4885MEN1 3820/4885MAPT 2520/4885
US-20140243286-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME BRDT, BRD4, BRD1 KMT2A 2014/4885MEN1 836/4885MAPT 1845/4885
US-20140243321-A1 BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME BRDT, BRD4, BRD1 KMT2A 1283/4885MEN1 257/4885MAPT 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.